




RECEIVED
JAN 14 2001
FILING DATE
APPROPRIATE
SUBCLASS
TECH CENTER
660012900
99/732,669



#3

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC10609ABTC	SERIAL NO. 09/732,669
	APPLICANT Todd A. Blumenkopf, et al.	
	FILING DATE December 8, 2000	GROUP 1624


U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US	5	3	8	9	5	0	9	2/14/95	Maskasky	430	567	
	US	6	1	8	0	6	3	6	1/30/01	Traxler, et al.	514	258	
VB	US	6	0	8	0	7	4	7	6/27/00	Uckun, et al.	514	259	
	US	6	1	3	6	5	9	5	10/24/00	Ihle, et al.	800	2	
	US	6	1	8	7	5	5	2	3/13/01	Roberds, et al.	436	501	

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
VB	WO	9	9	6	1	4	2	8	12/2/99	WO				
VB	WO	9	8	0	2	4	3	8	7/13/96					
VB	WO	9	8	0	2	4	3	7	7/13/96					
VB	WO	9	7	1	3	7	7	1	10/11/95					
VB	WO	9	7	2	8	1	6	1	8/7/97					
VB	WO	9	7	3	2	8	7	9	9/12/97					
VB	WO	9	7	4	9	7	0	6	12/31/97					
VB	WO	9	7	2	7	1	9	9	7/31/97					
VB	WO	9	8	0	7	7	2	6	2/26/98					
VB	WO	9	7	0	2	2	6	6	1/23/97					
VB	WO	0	0	0	0	2	0	2	1/6/00					
VB	WO	9	9	5	1	5	9	9	10/14/99					
VB	WO	9	7	1	8	2	1	2	5/22/97					
VB	EP	9	7	9	5	5	5	6	9/17/97	EP				
VB	WO	9	8	2	3	6	1	3	6/4/98	WO				
VB	WO	9	5	1	9	7	7	4	7/25/95					
VB	WO	9	8	3	3	7	9	8	8/6/98					
VB	WO	0	0	1	0	9	8	1	3/2/00					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			ATTY. DOCKET NO. PC10609ABTC	SERIAL NO. 09/732,669
			APPLICANT Todd A. Blumenkopf, et al.	
			FILING DATE December 8, 2000	GROUP 1614
VB		J. J. O'Shea, et al., <i>Phosphorylation and activation of the Jak-3 Janus Kinase in response to Interleukin-2</i> , <u>Nature</u> , 370, 151 (1994).		
VB		S. M. Russell, et al., <i>Interaction of IL-2RB and γc Chains with Jak1 and Jak3: Implications for XSCID and XCID</i> , <u>Science</u> , 266, 1042 (1994).		
VB		J. N. Ihle, <i>The Janus Protein Tyrosine Kinase Family and Its Role in Cytokine Signaling</i> , <u>Adv. Immunology</u> , 60, 1, (1995).		
VB		J. N. Ihle, <i>The Janus Protein Tyrosine Kinases in hematopoietic cytokine signaling</i> , <u>Semin. Immunology</u> , 7, 247, (1995).		
VB		T. Musso, et al., <i>Regulation of JAK3 Expression in Human Monocytes: Phosphorylation in Response to Interleukins 2, 4, and 7</i> , <u>J. Exp. Med.</u> , 181, 1425 (1995).		
VB		R. A. Kirken, et al., <i>Activation of JAK3, but not JAK1, is critical for IL-2-induced proliferation and STAT5 Recruitment by a COOH-terminal region of the IL-2 receptor β-chain</i> , <u>Cytokine</u> , 7 689, (1995).		
VB		M. G. Malabarba, et al., <i>Activation of JAK3, but not JAK1, is Critical to Interleukin-4 (IL4) Stimulated Proliferation and Requires a Membrane-proximal Region of IL4 Receptor α^*</i> , <u>J. Biol. Chem.</u> , 270, 9630, (1995).		
VB		J. H. Hanke, B. A. Pollok, and P. S. Changelian, <i>Role of tyrosine kinases in lymphocyte activation: Targets for drug intervention</i> , <u>Inflamm. Res.</u> , 44, 357, (1995).		
VB		E.E. Eynon, et al., <i>Disruption of Cytokine Signaling in Lymphoid Development: Unique Contributions of the Common Cytokine Gamma Chain and the JAK3 Kinase</i> , <u>J. Interferon Cytokine Res.</u> , 16, 677, (1996).		
VB		S. A. Oakes, et al., <i>Signaling via IL-2 and IL-4 in JAKβ-Deficient Severe Combined Immunodeficiency Lymphocytes: JAK3-Dependent and Independent Pathways</i> , <u>Immunity</u> , 5, 605 (1996).		
VB		J. D. Norangelo, et al, <i>Severe Combined Immune Deficiency due to Defects of the JAK3 Tyrosine Kinase</i> , <u>Prog. Immunodeficiency</u> , 6, 61, (1996).		
VB		D. C. Thomis, et al., <i>Peripheral Expression of JAK3 is Required to Maintain T Lymphocyte Function</i> , <u>J. Exp. Med.</u> , 185, 197, (1997).		
VB		B. H. Nelson, et al., <i>Requirement for an initial signal from the membrane-proximal region of the interleukin 2 receptor γc chain for Janus kinase activation leading to T cell proliferation</i> , <u>Proc. Natl. Acad. Sci. USA</u> , 94, 1878, (1997).		
VB		A. M. Baird, et al., <i>T Cell development and activation in Jak3-deficient mice</i> , <u>J. Leukocyte Biol.</u> , 63, 669, (1998).		
VB		K. D. Liu, et al., <i>JAK/STAT signaling by cytokine receptors</i> , <u>Curr. Opin. Immunol.</u>		
VB		W. J. Leonard and J. J. O'Shea, <i>JAKS and STATS: Biological Implications</i> , <u>Annu. Rev. Immunol.</u> , 16, 293, (1998).		
VB		F. Candotti, et al., <i>Severe combined immune deficiencies due to defects in the common γ chain-JAK3 signaling pathway</i> , <u>Springer Semin. Immunopathol.</u> , 19, 401, (1998).		
VB		R. Malaviya, et al., <i>Targeting Janus Kinase 3 in Mast Cells Prevents Immediate Hypersensitivity Reactions and Anaphylaxis</i> , <u>J. Biol. Chem.</u> , 274, 27028 (1999).		
VB		D. C. Thomis, et al., <i>The Jak Family Tyrosine Kinase Jak3 is Required for IL-2 Synthesis by Naïve/Resting CD4+ T Cells</i> , <u>J. Immunol.</u> , 163, 5411 (1999).		
VB		E. Chen, et al., <i>Advances in Cytokine Signaling: The Role of Jaks and STATs</i> , <u>Transplantation Proc.</u> , 31, 1482, (1999).		
VB		R. Moriggi, et al., <i>Stat5 Activation is Uniquely Associated with Cytokine Signaling in Peripheral T Cells</i> , <u>Immunity</u> , 11, 225 (1995).		
VB		L. H. Wang, et al., <i>JAK3, STAT, and MAPK Signaling Pathways as Novel Molecular Targets for the Tyrphostin AG-490 Regulation of IL-2-Mediated T Cell Response</i> , <u>J. Immunol.</u> , 162, 3897, (1999).		
VB		E. A. Sudbeck, et al., <i>Structure-based Design of Specific Inhibitors of Janus Kinase 3 as Apoptosis-inducing Antileukemic Agents</i> , <u>Clin. Cancer Res.</u> , 5, 1569, (1999).		



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC10609ABTC	SERIAL NO. 09/732,669
		APPLICANT Todd A. Blumenkopf, et al.	
		FILING DATE December 8, 2000	GROUP 1614
<input checked="" type="checkbox"/>	<input type="checkbox"/>	F. M. Uckun, et al., <i>In Vivo Toxicity and Pharmacokinetic Features of the Janus Kinase 3 Inhibitor WHI-P131 [40(4'-Hydroxyphenyl)-Amino-6,7-Dimethoxyquinazoline]</i> , Clin. Cancer Research, 5, 2954, (1999).	
<input checked="" type="checkbox"/>	<input type="checkbox"/>	E. A. Sudbeck and F. M. Uckun, <i>Recent Advances in JAK3 kinase inhibitors</i> , IDrugs, 2, 1026, (1999).	
<input checked="" type="checkbox"/>	<input type="checkbox"/>	R. Malaviya, et al., <i>Genetic and Biochemical Evidence for a Critical Role of Janus Kinase (JAK)-3 in Mast Cell-Mediated Type I Hypersensitivity Reactions</i> , Biochem. Biophys. Res. Commun., 257, 807, (1999).	
<input checked="" type="checkbox"/>	<input type="checkbox"/>	V. N. Trieu, et al., <i>A Specific Inhibitor of Janus Kinase-3 Increases Survival in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis</i> , Biochem. Biophys. Res. Commun., 267, 22, (2000).	
<input checked="" type="checkbox"/>	<input type="checkbox"/>	X. C. Li, et. al., <i>Blocking the Common γ-Chain of Cytokine Receptors Induces T Cell Apoptosis and Long-Term Islet Allograft Survival</i> , J. Immunol., 164, 1193 (2000)/	
<input checked="" type="checkbox"/>	<input type="checkbox"/>	R. Malaviya, et. al., <i>Treatment of allergic asthma by targeting Janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3',5'-Dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97)</i> , J. Pharmacol. Exp. Ther., 295, 912 (2000).	
<input checked="" type="checkbox"/>	<input type="checkbox"/>	S. Ghosh, et. al., <i>4-[(3-Bromo-4-hydroxyphenyl)amino]6,7-dimethoxyquinazolin-1-ium chloride methanol solvate and 4-[(3-hydroxyphenyl)amino]6,7-dimethoxy-1-quinazolinium chloride</i> , Acta Crystallogr., C: Cryst. Struct. Commun., C57, 76 (2001).	
<input checked="" type="checkbox"/>	<input type="checkbox"/>	E. A. Skudbeck, et. al. <i>An inhibitor of janus kinase 3: 4-(4-hydroxyphenylamino)-6,7-dimethoxyquinazolin-1-ium chloride</i> , Acta Crystallogr., SectC: Cryst. Struct. Commun., C56, 1282 (2000):	
EXAMINER		DATE CONSIDERED	
V. Balasubramanian		4/17/02	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			